Pharvaris NV, a late-stage biopharmaceutical company, has announced the upcoming presentation of clinical trial data concerning deucrictibant, an oral bradykinin B2 receptor antagonist, for the treatment of hereditary angioedema $(HAE)$. The data will be showcased at the US Hereditary Angioedema Association's 2025 National Summit, scheduled from July 10-13 in Baltimore, Maryland. The presentations will cover various aspects of deucrictibant, including its long-term safety and efficacy, its durability of response for on-demand treatment, and a comparison with standard care. These findings will be presented on July 11, 2025, during a poster session. The posters will also be accessible on Pharvaris' website.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。